Scleteri 7mg Tablet

Introduction

Scleteri is a prescription medication that contains the active ingredient Teriflunomide. It is available under the brand name Scleteri. Teriflunomide is primarily used for the treatment of multiple sclerosis (MS).

Uses

Scleteri is prescribed for the management of relapsing forms of multiple sclerosis (MS). It helps reduce the frequency of relapses and delays the progression of physical disability associated with MS.

Dosage and Administration

The dosage of Scleteri may vary depending on the individual’s condition and response to treatment. Follow the instructions provided by your healthcare professional. Generally, the recommended dose is one tablet (14 mg) taken orally once daily, with or without food.

Mechanism of Action

Teriflunomide, the active ingredient in Scleteri, works by inhibiting the proliferation of certain immune cells called lymphocytes. This helps reduce inflammation and damage to the nerve cells in the central nervous system, which is characteristic of multiple sclerosis.

Side Effects

Common side effects of Scleteri may include diarrhea, nausea, hair thinning, and elevated liver enzymes. These side effects are usually mild and may subside over time. However, if they persist or worsen, consult your healthcare provider.

Serious side effects of Scleteri are rare but can occur. These may include liver problems, decreased white blood cell count, and increased risk of infections. If you experience any unusual symptoms such as persistent fatigue, yellowing of the skin or eyes, or signs of infection (e.g., fever, sore throat), seek medical attention immediately.

Drug Interactions

Scleteri may interact with certain medications, including warfarin (an anticoagulant), leflunomide (a related medication), and other immunosuppressants. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, before starting Scleteri.

Precautions

Before taking Scleteri, inform your healthcare provider about any pre-existing medical conditions, including liver problems, kidney problems, or a history of infections. Scleteri may not be suitable for everyone, and your healthcare provider will assess the potential risks and benefits before prescribing it.

Scleteri should not be used during pregnancy, as it may harm the unborn baby. Use effective contraception during treatment and for a certain period after stopping the medication. Consult your healthcare provider for more information.

Storage

Patient Tips

• Take Scleteri exactly as prescribed by your healthcare provider. Do not change the dosage or stop the medication without consulting them.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• attend regular follow-up appointments with your healthcare provider to monitor your response to treatment and ensure the medication is working effectively.
• If you have any concerns or questions about your treatment with Scleteri, don’t hesitate to reach out to your healthcare provider for clarification and guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• AUBAGIO 14 mg film-coated tablets (Health Professionals SmPC) Available at:
• Teriflunomide (Drugs.com) [Accessed 6 Jun. 2024] (online) Available at:
• teriflunomide 14 mg tablet multiple sclerosis agents, general (RX) [Accessed 9 Jun. 2024] (online) Available at:
• Teriflunomide (MedlinePlus) [Accessed 0 Jun. 2024] (online) Available at:
• Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. [Accessed 4 Jun. 2024] Available at: